Year Published
- 2008 (0)
- 2009 (1) Apply 2009 filter
- 2010 (0)
- 2011 (2) Apply 2011 filter
- 2012 (0)
- 2013 (0)
- (-) Remove 2014 filter 2014
- 2015 (2) Apply 2015 filter
- 2016 (1) Apply 2016 filter
- 2017 (3) Apply 2017 filter
- (-) Remove 2018 filter 2018
- 2019 (0)
- 2020 (0)
- 2021 (0)
Research Topics
Populations
- Countries/Governments (0)
- Rural Populations (0)
- Smallholder Farmers (0)
- Women (0)
Types of Research
- Data Analysis (1) Apply Data Analysis filter
- Literature Review (1) Apply Literature Review filter
- Portfolio Review (0)
- Research Brief (0)
Geography
- (-) Remove East Africa Region and Selected Countries filter East Africa Region and Selected Countries
- (-) Remove Global filter Global
- South Asia Region and Selected Countries (2) Apply South Asia Region and Selected Countries filter
- Southern Africa Region and Selected Countries (0)
- Sub-Saharan Africa (2) Apply Sub-Saharan Africa filter
- West Africa Region and Selected Countries (0)
Dataset
- ASTI (0)
- FAOSTAT (0)
- Farmer First (0)
- LSMS & LSMS-ISA (1) Apply LSMS & LSMS-ISA filter
- Other Datasets (0)
Current search
- (-) Remove East Africa Region and Selected Countries filter East Africa Region and Selected Countries
- (-) Remove Monitoring & Evaluation filter Monitoring & Evaluation
- (-) Remove Research & Development filter Research & Development
- (-) Remove Environment & Climate Change filter Environment & Climate Change
- (-) Remove 2014 filter 2014
- (-) Remove Education & Training filter Education & Training
- (-) Remove Global filter Global
- (-) Remove 2018 filter 2018
The private sector is the primary investor in health research and development (R&D) worldwide, with investment annual investment exceeding $150 billion, although only an estimated $5.9 billion is focused on diseases that primarily affect low and middle-income countries (LMICs) (West et al., 2017b). Pharmaceutical companies are the largest source of private spending on global health R&D focused on LMICs, providing $5.6 billion of the $5.9 billion in total private global health R&D per year. This report draws on 10-K forms filed by Pharmaceutical companies with the U.S. Securities and Exchange Commission (SEC) in the year 2016 to examine the evidence for five specific disincentives to private sector investment in drugs, vaccines and therapeutics for global health R&D: scientific uncertainty, weak policy environments, limited revenues and market uncertainty, high fixed costs for research and manufacturing, and imperfect markets. 10-K reports follow a standard format, including a business section and a risk section which include information on financial performance, investment options, lines of research, promising acquisitions and risk factors (scientific, market, and regulatory). As a result, these filings provide a valuable source of information for analyzing how private companies discuss risks and challenges as well as opportunities associated with global health R&D targeting LMICs.
This research project examines the traits of Tanzanian farmers living in five different farming system-based sub-regions: the Northern Highlands, Sukumaland, Central Maize, Coastal Cassava, and Zanzibar. We conducted quantitative analysis on data from the Tanzania National Panel Survey (TNPS). We complimented this analysis with qualitative data from fieldwork conducted in the summer of 2011 and September 2013 to present a quantitatively and qualitatively informed profile of the “typical” agricultural household’s land use patterns, demographic dynamics, and key issues or production constraints in each sub-region.